Veru (NASDAQ:VERU) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen lowered shares of Veru (NASDAQ:VERU) from a sell rating to a strong sell rating in a research report report published on Saturday,Wall Street Zen reports.

A number of other analysts also recently issued reports on VERU. Weiss Ratings downgraded shares of Veru from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 16th. Oppenheimer reiterated an “outperform” rating on shares of Veru in a research note on Wednesday, October 14th. Finally, Westpark Capital initiated coverage on shares of Veru in a research report on Tuesday, October 6th. They set a “buy” rating for the company. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Veru has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

Veru Trading Down 1.8%

Shares of Veru stock opened at $2.19 on Friday. The stock has a fifty day simple moving average of $2.46 and a 200 day simple moving average of $2.50. Veru has a 12-month low of $2.05 and a 12-month high of $7.33. The company has a market capitalization of $37.34 million, a P/E ratio of -3.17 and a beta of -1.21.

Veru (NASDAQ:VERU) last posted its earnings results on Monday, August 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.02. On average, analysts predict that Veru will post -1.04 EPS for the current year.

Institutional Investors Weigh In On Veru

Several hedge funds and other institutional investors have recently modified their holdings of the stock. FNY Investment Advisers LLC purchased a new position in shares of Veru during the second quarter worth about $328,000. Renaissance Technologies LLC bought a new position in shares of Veru in the first quarter worth approximately $153,000. Finally, Royal Bank of Canada raised its stake in Veru by 69.3% in the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock valued at $27,000 after purchasing an additional 5,008 shares in the last quarter. 47.16% of the stock is currently owned by institutional investors.

Veru Company Profile

Veru Inc is a biopharmaceutical company focused on developing medicines for oncology and metabolic diseases. The company’s pipeline includes therapies intended to address cancer-related muscle wasting, obesity, and other conditions associated with the loss of lean body mass and physical function.

Veru’s principal investigational product is enobosarm, an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function in patients with cancer-related wasting and obesity.